Hemp Therapies Wiki / CBD Oil & Products

CBD Oil: Reported Uses and Regulatory Status

CBD’s regulatory and research status is narrower than the range of purposes consumers commonly report using it for. This page separates the one point of established regulatory approval from the broader, unproven landscape of self-directed use.

The One FDA-Approved Use

Epidiolex, a prescription drug made exclusively of purified CBD, is FDA-approved specifically for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex, in patients one year of age and older. This approval is specific to that drug, at its studied formulation and dosage, for those named conditions — it is not an approval of CBD generally, and it does not extend to hemp-derived CBD oil products sold outside the prescription drug system.

Self-Directed Consumer Use

Outside of Epidiolex, no CBD product is FDA-approved for any use. The FDA has not evaluated hemp-derived CBD oil products for safety or effectiveness for any condition, and no disease or symptom claim may lawfully be made about them. Consumers nonetheless commonly report using CBD oil self-directedly, as part of general daily or wellness routines, without this reflecting any verified or approved effect. That distinction — a single, narrow, drug-specific FDA approval on one hand, and widespread, unevaluated self-directed use on the other — is the central regulatory fact governing how CBD oil can accurately be described.

Summary

CBD’s only FDA-approved use is a prescription drug for three specific seizure disorders. Everything else — the broad range of purposes people report using hemp-derived CBD oil for — sits outside FDA evaluation entirely, and no claim of effect for any of those purposes has regulatory backing.